Correction: S-Adenosyl-Methionine and Betaine Improve Early Virological Response in Chronic Hepatitis C Patients with Previous Nonresponse

• DOI: 10.1371/annotation/1e4a3fa2-2189-441f-809c-4fbf077e34e8
• Publication Date: 2010-11-18T02:58:20Z
• Authors: Magdalena Filipowicz; Christine Bernsmeier; Luigi Terracciano; Francois H. T. Duong; Markus H. Heim
• Keywords: Pegylated interferon; Betaine; Hepatitis C

Background/Aims: Treatment of chronic hepatitis C (CHC) with pegylated interferon a (pegIFNa) and ribavirin results in sustained response approximately half patients.Viral interference IFNa signal transduction through the Jak-STAT pathway might be an important factor underlying treatment failure.S-adenosyl-L-methionine (SAMe) betaine potentiate signaling cultured cells that express virus (HCV) proteins, enhance inhibitory effect on HCV replicons.We have performed clinical study aim to evaluate efficacy safety addition SAMe CHC pegIFNa/ribavirin. Methods:In this open-label pilot study, 29 patients who failed previous therapy (peg)IFNa/ribavirin were treated SAMe, betaine, pegIFNa2b ribavirin.Treatment duration was 6 or 12 months, depending genotype, protocol comprised stopping rule at week if early virological (EVR) not achieved.Virological biochemical assessed throughout treatment.Results: enrolled according protocol.79% infected genotype 1, 72% had advanced fibrosis, 76% previously received pegIFNa/ribavirin, only 14% achieved EVR treatment.When medications, 17 (59%) showed EVR, 3 (10%) however (SVR).SAMe found safe when used Conclusion:The pegIFNa/ribavirin improves CHC.